Is Indaptus Therapeutics going out of business?

Indaptus Therapeutics, Inc. (INDP) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

Indaptus Therapeutics, Inc. (INDP) scores 13 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: 11782.79% (YoY)

Five questions, kept separate

Survival - Critical

3-6 mo of estimated runway from 2026-06-30, based on $11.6M of cash and short-term investments against $30.8M of annual burn. Adjusted shares outstanding increased 11782.8% over the comparison year.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Demanding

1.6% net-cash backing support a demanding pre-commercial Valuation assessment.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. It appears across 2 scanned filings. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Shares dilution YoY: 11782.79% (YoY)
• Filing event risk: Going-Concern Warning (-8 pts)
• Return on Assets: -173.92%
• Price / Earnings: Unprofitable (see Valuation)
• Effective Tax Rate: 0.00% (loss-making)

Read from filings through 2026-08-13.

Price as of 2026-09-26.